FDA Grants Accelerated Approval to Rocket Pharmaceuticals' Severe Leukocyte Adhesion Deficiency Treatment "Kresladi"
First LAD‑I Gene Therapy
The U.S. Food and Drug Administration (FDA) has granted Accelerated Approval to Rocket Pharmaceuticals' lentiviral gene therapy Kresladi (marnetegragene autotemcel) for the treatment of severe leukocyte adhesion deficiency‑1 (LAD‑I). This historic milestone provides the first one‑time curative option for patients with an ultra‑rare disease that previously had no viable alternative beyond hematopoietic stem cell transplantation (HSCT). The FDA accepted increased CD18 and CD11a expression as a surrogate endpoint and will require confirmatory trials to verify clinical benefit.
Innovative Clinical Data Demonstrating 100% Survival
Kresladi’s approval is based on compelling safety and efficacy data from a global Phase 1/2 trial involving nine pediatric patients. All nine participants were alive at the 12‑month post‑dose assessment, achieving a 100% overall survival rate, and survival was maintained through up to 24 months of follow‑up. Normalization of CD18 protein on immune cells markedly reduced severe infections and restored wound‑healing capacity. Because the therapy delivers a functional ITGB2 gene to the patient’s own CD34⁺ hematopoietic stem cells via a lentiviral vector, no immune rejection or serious treatment‑related adverse events were observed.
Financial Impact of Rare‑Disease Success and PRV Acquisition
Through this approval, Rocket Pharmaceuticals secured a Priority Review Voucher (PRV) that incentivizes rare‑disease drug development. The company entered a definitive agreement to sell the voucher in April 2026 for $180 million, generating substantial non‑dilutive funding. The proceeds will support the limited commercial launch of Kresladi and further investment in the company’s late‑stage cardiovascular gene‑therapy pipeline. Although the LAD‑I market is extremely small, the voucher sale enables early cost recovery and fuels continued platform research.
Opening a New Era for Immune and Gene‑Therapy Markets
The launch of Kresladi illustrates the expanding indication landscape for gene therapies beyond ophthalmic and neurological rare diseases to include hematologic and immune disorders. Worldwide, LAD‑I affects roughly 1 in 100,000 newborns; without an HLA‑matched sibling donor for HSCT, affected infants face a high risk of early mortality. Kresladi addresses donor scarcity by providing a definitive gene‑correction solution, establishing a next‑generation therapeutic model. The success is expected to accelerate development of pipelines targeting similar immune‑deficiency and genetic blood disorders.
Rocket Pharmaceuticals' Kresladi approval delivers the first one‑time curative gene‑therapy option for the ultra‑rare severe LAD‑I patient population—approximately 1 in 100,000 newborns—who previously had no alternatives beyond HSCT. While the commercial patient pool is limited to a few hundred individuals globally, the simultaneous acquisition and $180 million sale of a Priority Review Voucher provides significant non‑dilutive capital. The 100% survival and robust CD18 expression data from the Phase 1/2 study enhance the technical credibility of the company's broader gene‑therapy platform, including its cardiovascular programs. In the long term, the FDA’s willingness to rely on surrogate endpoints for ultra‑rare diseases reinforces a flexible regulatory pathway that will guide future gene‑editing developers in designing clinical and approval strategies.